Holen Sie sich die Stockscreener-App
0.9203
0.13%
-0.0012
Handel nachbörslich:
.92
-0.0003
-0.03%
Schlusskurs vom Vortag:
$0.9215
Offen:
$0.95
24-Stunden-Volumen:
810.40K
Relative Volume:
0.64
Marktkapitalisierung:
$109.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.91M
KGV:
-3.6563
EPS:
-0.2517
Netto-Cashflow:
$-22.73M
1W Leistung:
-4.14%
1M Leistung:
+13.69%
6M Leistung:
-5.12%
1J Leistung:
+33.96%
1-Tages-Spanne:
$0.92
$0.9785
1-Wochen-Bereich:
$0.91
$1.02
52-Wochen-Spanne:
$0.6884
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
(403) 670-7377
Adresse
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9203 | 109.98M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
480.18 | 120.61B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
620.14 | 65.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.65 | 53.02B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.17 | 39.26B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
178.17 | 36.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Oncolytics Biotech Inc (ONCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncolytics Biotech | 8-K: Current report - Moomoo
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech StockWeekly review and sector backdrop - AD HOC NEWS
Oncolytics Biotech | F-10POS: Others - Moomoo
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oncolytics Biotech Secures New Pelareorep Manufacturing Patent - The Globe and Mail
Oncolytics (ONCY) Secures New Patent for Pelareorep Manufacturin - GuruFocus
ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics - Yahoo Finance
Oncolytics receives U.S. patent for pelareorep manufacturing By Investing.com - Investing.com South Africa
Oncolytics Gets US Patent for Pelareorep Manufacturing Process - marketscreener.com
Oncolytics Biotech Inc - Baystreet.ca
Oncolytics receives U.S. patent for pelareorep manufacturing - Investing.com
Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process - TradingView
Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 - The Manila Times
New pelareorep patent extends Oncolytics Biotech (Nasdaq: ONCY) IP to 2044 - Stock Titan
US patent shields Oncolytics' pelareorep manufacturing process into 2044 - Stock Titan
Oncolytics Biotech® to Participate in a Panel Presentation at Ca - GuruFocus
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
JonesTrading Maintains Oncolytics Biotech(ONCY.US) With Hold Rating - Moomoo
Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights - ACCESS Newswire
ONCY: Promising GI cancer data and new patent strategies position pelareorep for major milestones - TradingView
ONCY: Pivotal data for a novel IV oncolytic virus in GI cancers expected by year-end - TradingView
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Biotech (ONCY) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention - Yahoo Finance
Oncolytics Biotech (NASDAQ: ONCY) director Stephen Glover files initial Form 3 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director 30,000 options - Stock Titan
VersaFi ferme les marchés - Barchart.com
ONCOLYTICS BIOTECH (ONCY) CMO awarded 260,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options at $1.06 - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) grants director Rigby 30,000 options - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director granted options on 30,000 shares at $1.06 - Stock Titan
ONCOLYTICS (ONCY) CFO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CBO receives 260,000 stock options at $1.06 exercise price - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) CEO awarded 755,000 options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives 30,000 stock options grant at $1.06 - Stock Titan
ONCOLYTICS (NASDAQ: ONCY) director awarded stock options on 30,000 shares - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) CTO awarded 260,000 stock options at $1.06 strike - Stock Titan
ONCOLYTICS BIOTECH (ONCY) director receives stock options on 30,000 shares - Stock Titan
145,000 stock options granted to Oncolytics (ONCY) COO McAdory - Stock Titan
ONCOLYTICS BIOTECH (NASDAQ: ONCY) director receives 96,000 stock options at $1.06 - Stock Titan
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):